Literature DB >> 10861569

The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma.

S E Coupland1, G Anastassiou, A Stang, H Schilling, I Anagnostopoulos, N Bornfeld, H Stein.   

Abstract

Malignant uveal melanoma is the commonest primary intraocular tumour in adults. It metastasizes frequently and 50% of patients die within 10 years of diagnosis. The expression of cyclin D1, p53, and MDM2 in uveal melanoma and their relationship to metastasis-free 5-year survival was determined, in order to investigate whether these proteins help to distinguish those patients with a favourable prognosis from those with a poorer one. Ninety-six eyes enucleated for uveal melanomas were immunohistochemically analysed for the protein expression of cyclin D1 and related cell-cycle markers, p53 and MDM2. The evaluation of the specimens was undertaken by two independent pathologists without knowledge of the outcome. Statistical analysis of clinical, morphological, and immunohistological features was performed. A 'favourable outcome' was defined as survival of at least 5 years after diagnosis, without metastases (n=57). An 'unfavourable outcome' was defined as death from metastases within the first 5 years after diagnosis of uveal melanoma (n=39). Cyclin D1 positivity (>15% positive tumour cells) as well as p53 positivity (>15% positive tumour cells) was associated with an unfavourable outcome (for cyclin D1: odds ratio=4. 2, 95% confidence interval 1.5-11.8, p=0.006; for p53: odds ratio=3. 2, 95% confidence interval 1.1-9.3, p=0.03). In addition, cyclin D1 positivity was associated with the presence of extraocular extension of the tumour (p=0.01), with the mixed or epithelioid cell type (p=0. 02), and with the tumour cell MIB-1 positivity (p=0.0001). MDM2 immunoreactivity of the tumour cells showed a potential correlation with clinical outcome (odds ratio=2.1, 95% confidence interval 0.8-5. 8, p=0.13). Multiple logistic regression models showed that cyclin D1 positivity is an independent prognostic factor after control for other prognostic markers. The expression of cyclin D1 in uveal melanoma is associated with a more aggressive course and histologically unfavourable disease. This could serve as a further independent prognostic factor in uveal melanoma. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861569     DOI: 10.1002/(SICI)1096-9896(200006)191:2<120::AID-PATH591>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  21 in total

1.  Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck.

Authors:  Manju L Prasad; Snehal G Patel; Jatin P Shah; Stacy Hoshaw-Woodard; Klaus J Busam
Journal:  Head Neck Pathol       Date:  2011-12-13

Review 2.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

Review 3.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

4.  Deregulation of the Rb and p53 pathways in uveal melanoma.

Authors:  M A Brantley; J W Harbour
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 5.  Drosophila as a Potential Model for Ocular Tumors.

Authors:  Daimark Bennett; Ekaterina Lyulcheva; Neville Cobbe
Journal:  Ocul Oncol Pathol       Date:  2015-04-09

Review 6.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

7.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

Review 8.  Emerging insights into the molecular pathogenesis of uveal melanoma.

Authors:  Solange Landreville; Olga A Agapova; J William Harbour
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

9.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

10.  High levels of Hdmx promote cell growth in a subset of uveal melanomas.

Authors:  Job de Lange; Amina Fas Teunisse; Matty Verlaan-de Vries; Kirsten Lodder; Suzanne Lam; Gregorius Pm Luyten; Federico Bernal; Martine J Jager; Aart G Jochemsen
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.